Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu

YIN Haoyuan¹  LI Ying¹  PAN Li¹  FENG Lei¹ 

[1] Department of Laboratory, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi 653100, China;

关键词: immune checkpoint inhibitors;    immune-related adverse events;    biomarkers;   

DOI  :  10.3971/j.issn.1000-8578.2021.20.0997

来源: DOAJ

【 摘 要 】

In recent years, tumor immunotherapy with immune checkpoint as the target has attracted much attention because of its remarkable efficacy. However, with the application of immune-checkpoint inhibitors (ICIs), more and more immune-related adverse events (irAEs) have been reported. IrAEs impose an additional risk of death on tumor patients treated with ICIs, limiting the widespread use of ICIs. To help patients actively prevent irAEs, biomarkers with the predictive value of irAEs are of great significance. This paper reviews the biomarkers with predictive value for irAEs from the aspects of serology, genetics and microbiology.

【 授权许可】

Unknown